ARTV's Phase III NK Cell Therapy Shows High Efficacy in Refractory RA
核心洞察
Artiva Biotherapeutics reported strong early efficacy and safety for its phase III natural killer cell therapy in refractory rheumatoid arthritis (搜索).
The FDA has agreed to a single pivotal trial design for the NK cell therapy in this refractory RA population.
The company said the therapy supports scalable manufacturing and outpatient administration, with funding secured through 2029.
Artiva Biotherapeutics reported strong early efficacy and safety data from a phase III program evaluating an natural killer (NK) cell therapy in refractory rheumatoid arthritis (搜索) (RA). The company presented the update at the Stifel 2026 Virtual Immunology and Inflammation Forum.
The FDA has agreed to a single pivotal trial for the program, according to the company. Artiva also said the therapy is designed for scalable manufacturing and outpatient administration, and that it is funded through 2029 to support clinical and commercial plans.